ArticleFrontiers in physiology2026
Norovirus infection in pediatric acute gastroenteritis: epidemiology and clinical features in Ezhou, China, 2023-2025.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Norovirus (NoV) is a major pathogen causing acute gastroenteritis (AGE) worldwide, imposing a substantial disease burden. This study aimed to investigate the epidemiological, clinical and genotypic characteristics of NoV infection in pediatric patients with AGE in Ezhou, central China. Methods: Between January 2023 and June 2025, we enrolled pediatric AGE patients from Ezhou Maternal and Child Health Hospital and collected their demographic profiles, clinical records and stool specimens, together with matched local meteorological data. All stool samples were screened for NoV using a commercial colloidal gold immunoassay kit. A randomly selected subset of NoV-positive samples was further subjected to genetic sequencing. Results: Among the 8,435 enrolled pediatric patients, 422 (5.0%) tested positive for NoV, with annual positivity rates of 4.24% (2023), 5.89% (2024), and 4.57% (January-June 2025). The positive cases comprised 259 males and 163 females. Children aged 1-2 years had the highest NoV positivity rate. The epidemic period spanned winter to spring, corresponding to ambient humidity of 66.5%-69.95%. Typical clinical presentations included fever, vomiting, watery diarrhea, dehydration, abdominal pain, convulsions, lethargy and electrolyte disturbances. Genetic sequencing identified three NoV genotypes across the 2.5-year surveillance period: GII.17, GII.3 and GII.4. Conclusions: NoV infection prevalence rose continuously in Ezhou during the 2.5-year study period, with seasonal peaks in winter and spring. GII.17 was the dominant genotype among sequenced isolates. Children aged 1-2 years constitute the highest-risk population and exhibit a wide range of clinical manifestations. Fecal colloidal gold immunoassay serves as a practical screening tool for NoV detection in pediatric populations at primary medical institutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.